[go: up one dir, main page]

MX2019002065A - Derivado de triazolopirazinona util como un inhibidor de pde1 humana. - Google Patents

Derivado de triazolopirazinona util como un inhibidor de pde1 humana.

Info

Publication number
MX2019002065A
MX2019002065A MX2019002065A MX2019002065A MX2019002065A MX 2019002065 A MX2019002065 A MX 2019002065A MX 2019002065 A MX2019002065 A MX 2019002065A MX 2019002065 A MX2019002065 A MX 2019002065A MX 2019002065 A MX2019002065 A MX 2019002065A
Authority
MX
Mexico
Prior art keywords
pde1 inhibitor
derivative useful
human pde1
triazolopyrazinone
human
Prior art date
Application number
MX2019002065A
Other languages
English (en)
Inventor
Shi Qing
David Rekhter Mark
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2019002065A publication Critical patent/MX2019002065A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a un compuesto de fórmula I o una sal del mismo farmacéuticamente aceptable, para usarse como un inhibidor de PDE1 humana. (ver Fórmula).
MX2019002065A 2016-08-25 2017-08-18 Derivado de triazolopirazinona util como un inhibidor de pde1 humana. MX2019002065A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662379372P 2016-08-25 2016-08-25
PCT/US2017/047479 WO2018039051A1 (en) 2016-08-25 2017-08-18 Triazolopyrazinone derivative useful as a human pde1 inhibitor

Publications (1)

Publication Number Publication Date
MX2019002065A true MX2019002065A (es) 2019-06-03

Family

ID=59762063

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002065A MX2019002065A (es) 2016-08-25 2017-08-18 Derivado de triazolopirazinona util como un inhibidor de pde1 humana.

Country Status (37)

Country Link
US (1) US10138244B2 (es)
EP (1) EP3504208B1 (es)
JP (1) JP6633246B2 (es)
KR (1) KR20190028544A (es)
CN (1) CN109641902B (es)
AR (1) AR109328A1 (es)
AU (1) AU2017317111A1 (es)
BR (1) BR112019000988A2 (es)
CA (1) CA3034828A1 (es)
CL (1) CL2019000487A1 (es)
CO (1) CO2019001644A2 (es)
CR (1) CR20190078A (es)
CY (1) CY1123406T1 (es)
DK (1) DK3504208T3 (es)
DO (1) DOP2019000021A (es)
EA (1) EA201990313A1 (es)
EC (1) ECSP19013196A (es)
ES (1) ES2800433T3 (es)
HR (1) HRP20201187T1 (es)
HU (1) HUE050419T2 (es)
JO (1) JOP20170164A1 (es)
LT (1) LT3504208T (es)
MA (1) MA46039B1 (es)
MD (1) MD3504208T2 (es)
ME (1) ME03791B (es)
MX (1) MX2019002065A (es)
PE (1) PE20190452A1 (es)
PH (1) PH12019500370A1 (es)
PL (1) PL3504208T3 (es)
PT (1) PT3504208T (es)
RS (1) RS60442B1 (es)
SG (1) SG11201901311WA (es)
SI (1) SI3504208T1 (es)
SV (1) SV2019005838A (es)
TN (1) TN2019000038A1 (es)
TW (1) TWI651323B (es)
WO (1) WO2018039051A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR112457A1 (es) * 2017-08-02 2019-10-30 Lilly Co Eli Derivados de [1,2,4]triazolo[4,3-a]pirazin-6(5h)-ona
AR112346A1 (es) 2017-08-10 2019-10-16 Lilly Co Eli Derivados de [1,2,4]triazolo
US11453673B2 (en) 2018-02-06 2022-09-27 Eli Lilly And Company Substituted [1,2,4]triazolo[4,3-a]pyrazines as phosphodiesterase inhibitors
WO2021035157A1 (en) * 2019-08-22 2021-02-25 Intra-Cellular Therapies, Inc. Organic compounds
WO2025059641A1 (en) 2023-09-14 2025-03-20 Eli Lilly And Company Pde1 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4354027A (en) 1980-05-19 1982-10-12 Usv Pharmaceutical Corporation Triazoloquinoxalin-4-ones
KR101555384B1 (ko) 2006-12-13 2015-09-23 아스카 세이야쿠 가부시키가이샤 퀴녹살린 유도체
WO2008103357A1 (en) 2007-02-21 2008-08-28 E. I. Du Pont De Nemours And Company Fungicidal tricyclic 1,2,4-triazoles
KR20130097178A (ko) 2010-09-07 2013-09-02 아스텔라스세이야쿠 가부시키가이샤 퀴녹살린 화합물
CA2877149C (en) * 2012-06-18 2021-01-19 Dart Neuroscience (Cayman) Ltd Substituted pyridine azolopyrimidine-5-(6h)-one compounds
WO2016022825A1 (en) * 2014-08-07 2016-02-11 Intra-Cellular Therapies, Inc. Organic compounds
US20160083400A1 (en) * 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic guanidine derivative
TW201629064A (zh) * 2014-10-10 2016-08-16 H 朗德貝克公司 作爲pde1抑制劑之三唑並吡酮
AR107456A1 (es) * 2016-02-12 2018-05-02 Lilly Co Eli Inhibidor de pde1

Also Published As

Publication number Publication date
CY1123406T1 (el) 2021-12-31
BR112019000988A2 (pt) 2019-05-14
JP6633246B2 (ja) 2020-01-22
JOP20170164A1 (ar) 2019-01-30
MA46039B1 (fr) 2020-09-30
WO2018039051A1 (en) 2018-03-01
CL2019000487A1 (es) 2019-07-12
US10138244B2 (en) 2018-11-27
RS60442B1 (sr) 2020-07-31
SI3504208T1 (sl) 2020-08-31
KR20190028544A (ko) 2019-03-18
EA201990313A1 (ru) 2019-07-31
EP3504208A1 (en) 2019-07-03
CA3034828A1 (en) 2018-03-01
TN2019000038A1 (en) 2020-07-15
TW201819379A (zh) 2018-06-01
US20180057494A1 (en) 2018-03-01
DK3504208T3 (da) 2020-07-27
AR109328A1 (es) 2018-11-21
HUE050419T2 (hu) 2020-12-28
HRP20201187T1 (hr) 2020-11-13
TWI651323B (zh) 2019-02-21
PL3504208T3 (pl) 2020-11-16
AU2017317111A1 (en) 2019-01-31
LT3504208T (lt) 2020-08-10
PH12019500370A1 (en) 2019-10-21
PT3504208T (pt) 2020-08-31
JP2019526567A (ja) 2019-09-19
DOP2019000021A (es) 2019-02-28
CR20190078A (es) 2019-04-05
CN109641902B (zh) 2021-06-08
MD3504208T2 (ro) 2020-08-31
SV2019005838A (es) 2019-04-04
SG11201901311WA (en) 2019-03-28
ES2800433T3 (es) 2020-12-30
CN109641902A (zh) 2019-04-16
ME03791B (me) 2021-04-20
ECSP19013196A (es) 2019-03-29
CO2019001644A2 (es) 2019-05-21
PE20190452A1 (es) 2019-03-29
EP3504208B1 (en) 2020-06-10

Similar Documents

Publication Publication Date Title
SA518400547B1 (ar) مشتقات بيرازولو بيريميدين كمثبط كيناز
PH12015502031B1 (en) Tetrahydropyrrolothiazine compounds
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
PH12017501523A1 (en) Selective bace1 inhibitors
UA117976C2 (uk) Сполуки амінопіримідинілу як інгібітори jak
MA39749A (fr) Dérivés de pipéridine-dione
MA40059A (fr) Inhibiteurs de la phosphatidylinositol 3-kinase
MX2016013265A (es) Análogos de compuestos de 4h-pirazolo[1,5-a]bencimidazol como inhibidores parp.
PH12019500875A1 (en) Pyridone compound as c-met inhibitor
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
PH12016501517B1 (en) Tetrazolone-substituted dihydropyridinone mgat2 inhibitors
IN2014DN07996A (es)
MY182634A (en) Pharmaceutical containing sodium-dependent phosphate transporter inhibitor
MY193239A (en) Novel b-lactamase inhibitors
AU2016330503A8 (en) Therapeutic compounds and methods of use thereof
PH12017501955A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease
CY1119540T1 (el) Υποκατασταθεντα απο γλυκοπυρανοσυλιο παραγωγα ινδολο-ουριας και η χρηση τους ως αναστολεις sglt
EA201791596A1 (ru) Пиразоловые соединения
MX2018002193A (es) Metodo de uso de quinoxalinilo-piperazinamida.